Published in Healthcare Mergers, Acquisitions and Ventures Week, August 4th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at PharmaGap.
Report 1: V: GAP) ("PharmaGap" or "the Company"), a Canadian biotechnology company developing novel compounds to treat cancer, today announced the purchase by Dundee Securities Corporation ("Dundee") of 2,000,000 common equity units ("Units") and 2,400,000 Series I Preferred Shares ("Series I Shares"), for a total investment by Dundee of $550,000.
Robert McInnis, President of PharmaGap said, "This issue provides the basis to complete the testing program underway at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.